用e-pharmacophore建模和分子动力学模拟来识别植物分子作为保护乳腺癌的异型和突变特异PI3K-α抑制剂

相关实验视频

Updated: Jun 4, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

Ajay Mili¹, Sumit Birangal², Jyothi Giridhar²

¹Department of Pharmacognosy, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.

|December 19, 2024

概括

研究人员确定了抑制PI3K-α的天然化合物,PI3K-α是乳腺癌的关键驱动因素. 这些新型抑制剂显示出更安全,更有效的癌症治疗的前景.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
计算化学计算化学

背景情况:

氨基酸3-激酶α (PI3K-α) 突变对癌症的发展至关重要,特别是在HR+/HER2-乳腺癌中.
突变PI3K-α激活PI3K/AKT/mTOR通路,促进瘤细胞的增殖和存活.

研究的目的:

为了确定可以特异抑制突变PI3K-α异型的自然化合物.
探索基于天然产品的乳腺癌治疗治疗策略.

主要方法:

使用Inavolisib药物 (PDB:8EXV) 创建了一个e-pharmacophore模型.
使用阶段选对自然化合物的Molport数据库进行了选.
对有前途的候选人进行分子对接和分子动力学模拟.

主要成果:

通过对接,确定了七种潜在的PI3K-α抑制化合物.
三种化合物 (STOCK1N-85097,STOCK1N-85998,STOCK1N-86060) 在模拟中表现出显著的稳定性和与PI3K-α的相互作用.
这些化合物在各种计算分析中显示出有利的结果 (RMSD,RMSF,Rg,SASA,PCA,FEL).

结论:

已识别的天然化合物是突变PI3K-α的潜在抑制剂.
这些化合物可能提供一种治疗方法,其副作用可能比传统治疗方法少.
需要进一步的体外和体内验证,以确认疗效和安全性.

关键词:

乳腺癌乳腺癌乳腺癌这是E-药.分子动力学分子动力学天然化合物是一种自然化合物.这是一种PI3K-α抑制剂.

更多相关视频

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

An In Vitro Dormancy Model of Estrogen-sensitive Breast Cancer in the Bone Marrow: A Tool for Molecular Mechanism Studies and Hypothesis Generation

Published on: June 30, 2015

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Phosphoinositides and PIPs

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...